Evelyn Partners Investment Management LLP Buys 4,783 Shares of Thermo Fisher Scientific Inc. $TMO

Evelyn Partners Investment Management LLP raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 109,140 shares of the medical research company’s stock after buying an additional 4,783 shares during the quarter. Thermo Fisher Scientific comprises 1.5% of Evelyn Partners Investment Management LLP’s portfolio, making the stock its 17th biggest position. Evelyn Partners Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $53,646,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Excelsior Advisor Network LLC grew its holdings in shares of Thermo Fisher Scientific by 7.4% in the 1st quarter. Excelsior Advisor Network LLC now owns 857 shares of the medical research company’s stock valued at $421,000 after buying an additional 59 shares during the period. Quantinno Capital Management LP raised its stake in Thermo Fisher Scientific by 11.6% during the 1st quarter. Quantinno Capital Management LP now owns 188,243 shares of the medical research company’s stock worth $92,527,000 after buying an additional 19,597 shares during the period. Southpoint Capital Advisors LP lifted its holdings in Thermo Fisher Scientific by 300.0% during the first quarter. Southpoint Capital Advisors LP now owns 400,000 shares of the medical research company’s stock worth $196,612,000 after acquiring an additional 300,000 shares in the last quarter. Teca Partners LP grew its stake in Thermo Fisher Scientific by 81.5% in the first quarter. Teca Partners LP now owns 31,939 shares of the medical research company’s stock valued at $15,699,000 after acquiring an additional 14,339 shares during the period. Finally, Jessup Wealth Management Inc raised its position in shares of Thermo Fisher Scientific by 9.0% during the first quarter. Jessup Wealth Management Inc now owns 714 shares of the medical research company’s stock worth $351,000 after purchasing an additional 59 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.7%

NYSE TMO opened at $558.79 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock’s 50 day moving average price is $496.34 and its two-hundred day moving average price is $512.33. The stock has a market capitalization of $207.66 billion, a price-to-earnings ratio of 30.06, a PEG ratio of 2.51 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $617.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.